EGFR (A763_Y764insFQEA)

EGFR · Variant type: indel · HGVS: p.A763_Y764insFQEA

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Mobocertinib	99.4%	0.6%	97.22
2	Canertinib	99.3%	0.7%	96.49
3	Neratinib	99.3%	0.7%	93.18
4	Lazertinib	99.1%	0.9%	97.47
5	Erlotinib	98.5%	1.5%	99.75
6	Pralsetinib	98.5%	1.5%	93.43
7	Osimertinib	97.9%	2.1%	97.24
8	Vandetanib	97.4%	2.6%	95.74
9	Dacomitinib	96.6%	3.4%	97.99
10	Fostamatinib	96.5%	3.5%	96.74
11	Brigatinib	93.4%	6.6%	82.96
12	Pacritinib	82.0%	18.0%	88.64
13	Lapatinib	67.6%	32.4%	99.25
14	Alpelisib	59.1%	40.9%	97.22
15	Defactinib	54.6%	45.4%	92.68
16	Gilteritinib	54.3%	45.7%	88.97
17	Zanubrutinib	51.5%	48.5%	98.24
18	Ibrutinib	36.6%	63.4%	94.74
19	Temsirolimus	28.0%	72.0%	100.00
20	Capmatinib	27.8%	72.2%	99.75
21	Pemigatinib	27.8%	72.2%	98.23
22	Regorafenib	22.9%	77.1%	95.99
23	Pirtobrutinib	21.7%	78.3%	99.49
24	Pazopanib	16.2%	83.8%	97.49
25	Everolimus	15.8%	84.2%	100.00

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Mobocertinib	99.4%	100.0%	-0.6%
Canertinib	99.3%	98.4%	+0.9%
Neratinib	99.3%	100.0%	-0.7%
Lazertinib	99.1%	100.0%	-0.9%
Erlotinib	98.5%	99.4%	-0.9%
Pralsetinib	98.5%	99.1%	-0.7%
Osimertinib	97.9%	99.1%	-1.2%
Vandetanib	97.4%	99.3%	-1.9%
Dacomitinib	96.6%	99.8%	-3.2%
Fostamatinib	96.5%	97.8%	-1.2%
Brigatinib	93.4%	98.5%	-5.1%
Pacritinib	82.0%	—	—
Lapatinib	67.6%	99.2%	-31.5%
Alpelisib	59.1%	—	—
Defactinib	54.6%	94.6%	-39.9%
Gilteritinib	54.3%	91.0%	-36.7%
Zanubrutinib	51.5%	88.2%	-36.7%
Ibrutinib	36.6%	99.3%	-62.7%
Temsirolimus	28.0%	—	—
Capmatinib	27.8%	—	—
Pemigatinib	27.8%	—	—
Regorafenib	22.9%	—	—
Pirtobrutinib	21.7%	—	—
Pazopanib	16.2%	—	—
Everolimus	15.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms